July 12th 2024
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss how to decide on treatment for patients with advanced or metastatic HER2-positive breast cancer who have central nervous system metastases.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.
January 24th 2023
Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
October 20th 2022
Dr. Neil M. Iyengar closes the discussion with preliminary results from a phase I study, thoughts on use of biosimilars, and other in-progress trials of interest.
Clinically relevant advice for the monitoring and management of pulmonary complications in patients with HER2+ mBC.
October 13th 2022
Discussion centered around the latest data and guideline updates, and how these changes affect therapy sequencing in the first, second, and third lines of treatment.
Insights concerning the selection of effective treatment approaches for patients with HER2+ mBC presenting with brain metastases and other complications.
October 6th 2022
An expert breast medical oncologist discusses recent changes to HER2+ mBC treatment guidelines due to key findings from the DESTINY-Breast03 trial.
Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.
April 29th 2022
A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.
Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.
April 22nd 2022
Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.
Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.
April 15th 2022
Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.
Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.
April 8th 2022
Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.
Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.